

Access DB# 64451

## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: PATEL SUDHAKER Examiner #: 77018 Date: 4/22/02  
 Art Unit: 1624 Phone Number 30 84769 Serial Number: 10026608  
 Mail Box and Bldg/Room Location: CM1 4E18 Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. MEJ


\*\*\*\*\*  
 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

TRICYCLIC COMPOUND SPIRO UNION  
 Title of Invention:

Inventors (please provide full names): HIDEMITSU NISHIDA et al.

Earliest Priority Filing Date: 6/30/1999

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



IMPORTANT SPECIES

Point of Contact:  
 Barb O'Brien  
 Technical Information Specialist  
 STIC CM1 6A05 308-4291

Point of Contact:  
 Toby Port  
 Technical Info. Specialist  
 CM1 6A04  
 703-308-3534

Need info @ gels, compositions & method of use as anticoagulants or inhibitors for blood coagulation. Copy of claims enclosed. THA  
1624

## STAFF USE ONLY

Searcher: T. Port + B.O. Bryen

Searcher Phone #: \_\_\_\_\_

Searcher Location: \_\_\_\_\_

Date Searcher Picked Up: 4/22

Date Completed: 4/24

Searcher Prep & Review Time: 120

Clerical Prep Time: \_\_\_\_\_

Online Time: 155

## Type of Search

NA Sequence (#) \_\_\_\_\_

AA Sequence (#) \_\_\_\_\_

Structure (#) 8

Bibliographic \_\_\_\_\_

Litigation \_\_\_\_\_

Fulltext \_\_\_\_\_

Patent Family \_\_\_\_\_

Other \_\_\_\_\_

## Vendors and cost where applicable

STN 761

Dialog \_\_\_\_\_

Questel/Orbit \_\_\_\_\_

Dr. Link \_\_\_\_\_

Lexis/Nexis \_\_\_\_\_

Sequence Systems \_\_\_\_\_

WWW/Internet \_\_\_\_\_

Other (specify) \_\_\_\_\_

=> file reg; d stat que l18  
FILE 'REGISTRY' ENTERED AT 11:34:29 ON 26 APR 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 24 APR 2002 HIGHEST RN 407577-00-8  
DICTIONARY FILE UPDATES: 24 APR 2002 HIGHEST RN 407577-00-8


TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L9 STR




*Full file search done looking for  
any of the following 8 structures (L9-L16)*

VAR G1=N/C  
VAR G3=O/N/S  
REP G4=(0-2) C  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 14


STEREO ATTRIBUTES: NONE  
L10 STR



VAR G1=N/C  
 VAR G3=O/N/S  
 REP G4=(0-2) C  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 15


STEREO ATTRIBUTES: NONE  
 L11 STR



VAR G1=N/C  
 VAR G3=O/N/S  
 REP G4=(0-2) C  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 14


STEREO ATTRIBUTES: NONE  
 L12 STR



VAR G1=N/C  
 VAR G3=O/N/S  
 REP G4=(0-2) C  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 15


STEREO ATTRIBUTES: NONE  
 L13 STR



VAR G1=N/C  
 VAR G3=O/N/S  
 REP G4=(0-2) C  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 15


STEREO ATTRIBUTES: NONE  
 L14 STR



VAR G1=N/C  
 VAR G3=O/N/S  
 REP G4=(0-2) C  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE  
 L15 STR




VAR G1=N/C  
 VAR G3=O/N/S  
 REP G4=(0-2) C  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L16 STR



VAR G1=N/C  
 VAR G3=O/N/S  
 REP G4=(0-2) C  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L18 147 SEA FILE=ZREGISTRY SSS FUL (L9 OR L10 OR L11 OR L12 OR L13 OR  
 L14 OR L15 OR L16)

100.0% PROCESSED 18509 ITERATIONS  
 SEARCH TIME: 00.00.05

147 ANSWERS

=> file caplus; d que nos l19  
 FILE 'CAPLUS' ENTERED AT 11:34:43 ON 26 APR 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Apr 2002 VOL 136 ISS 17  
 FILE LAST UPDATED: 24 Apr 2002 (20020424/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.



CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L9 STR  
 L10 STR  
 L11 STR  
 L12 STR  
 L13 STR  
 L14 STR  
 L15 STR  
 L16 STR  
 L18 147 SEA FILE=ZREGISTRY SSS FUL (L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR L16)  
 L19 1 SEA FILE=CAPLUS ABB=ON PLU=ON L18

=> d ibib abs hitstr l19 1

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2001:31501 CAPLUS  
 DOCUMENT NUMBER: 134:100887  
 TITLE: Preparation of tricyclic compounds having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants  
 INVENTOR(S): Nishida, Hidemitsu; Saitoh, Fumihiko; Harada, Kousuke; Shiromizu, Ikuya  
 PATENT ASSIGNEE(S): Mochida Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 305 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002397	A1	20010111	WO 2000-JP4374	20000630
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1191028	A1	20020327	EP 2000-940912	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001006402	A	20020227	NO 2001-6402	20011228
PRIORITY APPLN. INFO.: JP 1999-222883 A 19990630				
WO 2000-JP4374 W 20000630				
OTHER SOURCE(S): MARPAT 134:100887				
GI				



AB Arom. compds. having cyclic amino which are represented by general formula (I) or salts thereof [wherein A = H, (un)substituted (un)satd. 5- to 6-membered cyclic hydrocarbyl or heterocyclyl, (un)substituted NH<sub>2</sub>, (un)substituted imidoyl; B = single bond, CO, SO, (un)substituted Cl-2 alkylene; D = H, (un)substituted CHO, (un)substituted Cl-6 alkyl; X = N, (un)substituted methine; Y = O, S(O)<sub>y</sub> (wherein y = 0,1,2), (un)substituted NH; Z = CH<sub>2</sub>, CO, C(S); T = S(O)<sub>z</sub> (wherein z = 0,1,2), CO, (un)substituted Cl-2 alkylene; Q = (un)substituted hydrocarbyl or heterocyclyl; m, n, q = 0, 1,2; p = 0,1; the three rings contg. X, Y, or Z is optionally substituted; the bond represented by a dotted and solid line in the ring contg. Z is a single bond or a double bond when p = 0] are prepd. These compds. are useful as drugs, in particular, activated blood coagulation factor X inhibitors for the prevention and treatment of diseases caused by thrombus or embolism, influenza virus infection, or periodontosis, exert a potent anticoagulation effect, and can be orally administered. A pharmacophore derived from the above compds. is also useful in mol. designing Fxa inhibitors. Thus, 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine was cyclocondensed with Et 2-[N-(3-acetoxy-2-oxopropan-1-yl)-N-(6-chloronaphthalene-2-ylsulfonyl)amino]acetate under reflux in the presence of p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H.H<sub>2</sub>O using a Dean-Stark trap to give 6-acetoxy-1,4-diaza-1'-benzyl-4-(6-chloronaphthalene-2-ylsulfonyl)-7-oxaspiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one which underwent sapon. with a mixt. of aq. NaOH and MeOH, methylation by di-Me sulfate, and debenzylation with 1-chloroethyl chloroformate to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxaspiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one hydrochloride. The latter compd. was condensed with 4-chloropyridine hydrochloride in the presence of diisopropylethylamine in 2-ethoxyethanol under reflux for 2 h to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxo-1'-(4-pyridyl)-spiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one (II; R = CH<sub>2</sub>OMe). II (R = CH<sub>2</sub>OMe) and II (R = CO<sub>2</sub>Et) showed IC<sub>50</sub> of 0.0032 and 0.0015 .mu.M, resp., against Fxa.

IT 318986-36-6P 318986-38-8P 318987-69-8P  
318987-70-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tricyclic compds. having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants or as pharmacophores in mol. designing Fxa inhibitors)




RN 318986-36-6 CAPLUS  
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-  
pyridinyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 318986-38-8 CAPLUS  
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-  
pyridinyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 318987-69-8 CAPLUS  
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
ethyl ester, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 318987-70-1 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
ethyl ester, (-)-(9CI) (CA INDEX NAME)

Rotation (-).



IT 318986-22-0P 318986-60-6P 318986-68-4P  
 318986-74-2P 318986-78-6P 318986-80-0P  
 318986-91-3P 318987-02-9P 318987-14-3P  
 318987-18-7P 318987-29-0P 318987-31-4P  
 318987-33-6P 318987-35-8P 318987-37-0P  
 318987-39-2P 318987-41-6P 318987-44-9P  
 318987-46-1P 318987-51-8P 318987-52-9P  
 318987-54-1P 318987-55-2P 318987-56-3P  
 318987-60-9P 318987-61-0P 318987-62-1P  
 318987-63-2P 318987-64-3P 318987-65-4P  
 318987-66-5P 318987-67-6P 318987-72-3P  
 318987-73-4P 318987-74-5P 318987-75-6P  
 318987-76-7P 318987-77-8P 318987-78-9P  
 318987-79-0P 318987-80-3P 318987-81-4P  
 318987-82-5P 318987-83-6P 318987-84-7P  
 318987-85-8P 318987-86-9P 318987-87-0P  
 318987-88-1P 318987-90-5P 318987-91-6P  
 318987-95-0P 318987-96-1P 318987-97-2P  
 318987-98-3P 318987-99-4P 318988-01-1P  
 318988-02-2P 318988-04-4P 318988-06-6P  
 318988-07-7P 318988-08-8P 318988-09-9P  
 318988-10-2P 318988-13-5P 318988-15-7P  
 318988-16-8P 318988-20-4P 318988-21-5P  
 318988-25-9P 318988-26-0P 318988-29-3P  
 318988-30-6P 318988-31-7P 318988-32-8P


318988-33-9P 318988-38-4P 318988-39-5P  
318988-40-8P 318988-41-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tricyclic compds. having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants or as pharmacophores in mol. designing Fxa inhibitors)


RN 318986-22-0 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 318986-60-6 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 318986-68-4 CAPLUS

CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 318986-74-2 CAPLUS

CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]- (9CI) (CA INDEX NAME)




RN 318986-78-6 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(methoxymethyl)-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 318986-80-0 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 318986-91-3 CAPLUS


CN Spiro[piperidine-4,3'-(4'H)-[2H,6H]pyrazino[2,1-b][1,3]oxazin]-6'-one, 8'-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-9'a-(methoxymethyl)-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318987-02-9 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI)  
 (CA INDEX NAME)




RN 318987-14-3 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyrimidinyl)- (9CI)  
 (CA INDEX NAME)



RN 318987-18-7 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[[ (1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]tetrahydro-1'-(4-pyridinyl)-  
 (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 318987-29-0 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-  
 pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 318986-22-0  
 CMF C27 H29 Cl N4 O5 S



CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 318987-31-4 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-  
 pyridinyl)-, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318986-38-8  
 CMF C27 H29 Cl N4 O5 S


Rotation (-).



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 318987-33-6 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-  
pyridinyl)-, monomethanesulfonate (salt) (9CI). (CA INDEX NAME)

CM 1

CRN 318986-64-0


CMF C26 H27 Cl N4 O5 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 318987-35-8 CAPLUS

CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]-, ethyl ester, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318986-68-4


CMF C30 H33 Cl N4 O7 S



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 318987-37-0 CAPLUS


CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318986-80-0


CMF C28 H29 Cl N4 O6 S





CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 318987-39-2 CAPLUS  
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-,  
monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 318987-02-9  
CMF C25 H25 Cl N4 O4 S



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 318987-41-6 CAPLUS  
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyrimidinyl)-,  
monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 318987-14-3  
CMF C24 H24 Cl N5 O4 S



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 318987-44-9 CAPLUS  
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[[ (1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]tetrahydro-1'-(4-pyridinyl)-,  
monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-18-7  
CMF C23 H25 Cl N4 O4 S


Double bond geometry as shown.



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 318987-46-1 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-methoxyethoxy)methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 318987-51-8 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-methoxyethoxy)methyl]-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-46-1


CMF C29 H33 Cl N4 O6 S



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 318987-52-9 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-  
hydroxyethoxy)methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 318987-54-1 CAPLUS

CN Pyridinium, 4-[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-  
(methoxymethyl)-5-oxospiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-  
1'-yl]-1-methyl-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA  
INDEX NAME)

CM 1

CRN 318987-53-0


CMF C28 H32 Cl N4 O5 S



CM 2


CRN 16722-51-3

CMF C7 H7 O3 S




RN 318987-55-2 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine], 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 318987-56-3 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 318987-60-9 CAPLUS


CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,

7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
ethyl ester, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-56-3


CMF C28 H29 Cl N4 O6 S



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 318987-61-0 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)




RN 318987-62-1 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
methyl ester (9CI) (CA INDEX NAME)




RN 318987-63-2 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 318987-64-3 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, propyl ester (9CI) (CA INDEX NAME)




RN 318987-65-4 CAPLUS


CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 318987-66-5 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 318987-67-6 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 318987-72-3 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
 ethyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 318987-70-1  
 CMF C28 H29 Cl N4 O6 S

Rotation (-).

Prepared by Toby Port & Barb O'Bryen, 308-3534






CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 318987-73-4 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
(-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 318987-74-5 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
methyl ester, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 318987-75-6 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
1-methylethyl ester, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 318987-76-7 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
propyl ester, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 318987-77-8 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
2-propenyl ester, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 318987-78-9 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
2-methoxyethyl ester, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 318987-79-0 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
1,1-dimethylethyl ester, (-)-(9CI) (CA INDEX NAME)

Rotation (-).



RN 318987-80-3 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,


7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, methyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-74-5

CMF C27 H27 Cl N4 O6 S


Rotation (-).



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 318987-81-4 CAPLUS


CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 1-methylethyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-75-6

CMF C29 H31 Cl N4 O6 S


Rotation (-).



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 318987-82-5 CAPLUS


CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
propyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-76-7

CMF C29 H31 Cl N4 O6 S


Rotation (-).



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 318987-83-6 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
 2-propenyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-77-8

CMF C29 H29 Cl N4 O6 S


Rotation (-).



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 318987-84-7 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
 2-methoxyethyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-78-9


CMF C29 H31 Cl N4 O7 S

Rotation (-).



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 318987-85-8 CAPLUS  
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
1,1-dimethylethyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 318987-79-0  
CMF C30 H33 Cl N4 O6 S

Rotation (-).




CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 318987-86-9 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
 ammonium salt (9CI) (CA INDEX NAME)



● NH<sub>3</sub>

RN 318987-87-0 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
 ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




● NH<sub>3</sub>

RN 318987-88-1 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
 ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● NH<sub>3</sub>

RN 318987-90-5 CAPLUS  
 CN Pyridinium, 4-[7-[(6-chloro-2-naphthalenyl)sulfonyl]-8a-(ethoxycarbonyl)tetrahydro-5-oxospiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-1'-yl]-1-ethyl-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 318987-89-2  
 CMF C30 H34 Cl N4 O6 S




CM 2

CRN 16722-51-3  
 CMF C7 H7 O3 S




RN 318987-91-6 CAPLUS  
 CN Benzenecarboximidamide, 4-[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-5-oxospiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-1'-yl]- (9CI) (CA INDEX NAME)




RN 318987-95-0 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-  
pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 318987-96-1 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(1-  
oxido-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318987-97-2 CAPLUS


CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(1-iminoethyl)- (9CI)  
(CA INDEX NAME)



RN 318987-98-3 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(1-iminoethyl)-,  
 monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 318987-97-2  
 CMF C22 H25 Cl N4 O4 S




CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 318987-99-4 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 8a-(aminomethyl)-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-  
 pyridinyl)- (9CI) (CA INDEX NAME)




RN 318988-01-1 CAPLUS

CN Carbamic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 318988-02-2 CAPLUS

CN Glycine, N-[[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 318988-04-4 CAPLUS


CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(4-morpholinylmethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-06-6 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(4-morpholinylmethyl)-  
 1'-(4-pyridinyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 318988-04-4  
 CMF C30 H34 Cl N5 O5 S




CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 318988-07-7 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]-1'-(2-chloro-  
 4-pyrimidinyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 318988-08-8 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
8a-[(acetyloxy)methyl]tetrahydro-7-[(2-naphthalenylsulfonyl)-1'-(4-  
pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 318988-09-9 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-  
pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 318988-10-2 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-  
pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 318988-13-5 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 318988-15-7 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 318988-16-8 CAPLUS


CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-methyl-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-20-4 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-methyl-1'-(4-pyridinyl)-  
 , monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 318988-16-8  
 CMF C26 H27 Cl N4 O4 S




CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 318988-21-5 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-butanoic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
 methyl ester (9CI) (CA INDEX NAME)






RN 318988-25-9 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-butanoic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-,  
ammonium salt (9CI) (CA INDEX NAME)

● NH<sub>3</sub>


RN 318988-26-0 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-  
pyridinyl)- (9CI) (CA INDEX NAME)




RN 318988-29-3 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1-  
methyl-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-30-6 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1-  
methyl-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 318988-31-7 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1-  
methyl-1'-(4-pyridinyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318988-30-6


CMF C28 H32 Cl N5 O4 S



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 318988-32-8 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-  
pyridinyl)- (9CI) (CA INDEX NAME)




RN 318988-33-9 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
1-acetyl-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-  
(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-38-4 CAPLUS


CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
tetrahydro-8a-(methoxymethyl)-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)



RN 318988-39-5 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,


tetrahydro-8a-(methoxymethyl)-1-methyl-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-40-8 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
tetrahydro-8a-(methoxymethyl)-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)-  
, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 318988-41-9 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
tetrahydro-8a-(methoxymethyl)-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)-  
, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT 318986-28-6P 318986-30-0P 318986-32-2P  
318986-34-4P 318986-40-2P 318986-42-4P  
318986-44-6P 318986-57-1P 318986-62-8P  
318986-64-0P 318986-66-2P 318986-70-8P


318986-72-0P 318986-76-4P 318986-89-9P  
 318986-93-5P 318986-96-8P 318986-98-0P  
 318987-00-7P 318987-09-6P 318987-11-0P  
 318987-16-5P 318987-25-6P 318987-27-8P  
 318987-47-2P 318987-48-3P 318987-49-4P  
 318987-50-7P 318987-57-4P 318987-58-5P  
 318987-59-6P 318987-71-2P 318987-93-8P  
 318987-94-9P 318988-00-0P 318988-03-3P  
 318988-05-5P 318988-11-3P 318988-12-4P  
 318988-14-6P 318988-18-0P 318988-19-1P  
 318988-23-7P 318988-24-8P 318988-27-1P  
 318988-28-2P 318988-34-0P 318988-35-1P  
 318988-36-2P 318988-37-3P 318988-45-3P  
 318988-46-4P 318988-47-5P 318988-48-6P,  
 1,4-Diaza-6-(hydroxymethyl)-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-  
 piperidine]-2-one 318988-49-7P 318988-53-3P  
 318988-54-4P 318988-55-5P 318988-56-6P  
 318988-57-7P 318988-58-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(prepn. of tricyclic compds. having spiro-piperidine as inhibitors of  
 blood coagulation factor X (FXa) and anticoagulants or as  
 pharmacophores in mol. designing Fxa inhibitors)


RN 318986-28-6 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 318986-30-0 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 318986-32-2 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 318986-34-4 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-,  
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 318986-40-2 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-5-oxo-,  
 phenylmethyl ester (9CI) (CA INDEX NAME)




RN 318986-42-4 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-5-oxo-,  
 phenylmethyl ester (9CI) (CA INDEX NAME)




RN 318986-44-6 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)- (9CI)  
 (CA INDEX NAME)



RN 318986-57-1 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)- (9CI)  
 (CA INDEX NAME)




RN 318986-62-8 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 318986-64-0 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-  
pyridinyl)- (9CI) (CA INDEX NAME)




RN 318986-66-2 CAPLUS  
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 318986-70-8 CAPLUS  
CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(  
phenylmethyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-  
yl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 318986-72-0 CAPLUS  
CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-  
oxospiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]-,  
ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)






● HCl


RN 318986-76-4 CAPLUS  
 CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 318986-89-9 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 318986-93-5 CAPLUS  
 CN Spiro[piperidine-4,3'-(4'H)-[2H,6H]pyrazino[2,1-b][1,3]oxazin]-6'-one, 9'a-[(acetyloxy)methyl]-8'-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 318986-96-8 CAPLUS

CN Spiro[piperidine-4,3'-(4'H)-[2H,6H]pyrazino[2,1-b][1,3]oxazin]-6'-one,  
8'-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-9'a-(hydroxymethyl)-1-  
(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 318986-98-0 CAPLUS

CN Spiro[piperidine-4,3'-(4'H)-[2H,6H]pyrazino[2,1-b][1,3]oxazin]-6'-one,  
8'-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-9'a-(methoxymethyl)-1-  
(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 318987-00-7 CAPLUS

CN Spiro[piperidine-4,3'-(4'H)-[2H,6H]pyrazino[2,1-b][1,3]oxazin]-6'-one,  
8'-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-9'a-(methoxymethyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 318987-09-6 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(phenylmethyl)- (9CI)  
 (CA INDEX NAME)




RN 318987-11-0 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-, monohydrochloride (9CI)  
 (CA INDEX NAME)




● HCl

RN 318987-16-5 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-[2-(methylthio)-4-  
 pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 318987-25-6 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[[ (1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]tetrahydro-1'-(phenylmethyl)-  
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 318987-27-8 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[[ (1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]tetrahydro-, monohydrochloride  
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl


RN 318987-47-2 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]-8a-[(2-ethoxy-2-  
 oxoethoxy)methyl]tetrahydro-5-oxo-, phenylmethyl ester (9CI) (CA INDEX  
 NAME)



RN 318987-48-3 CAPLUS


CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-  
hydroxyethoxy)methyl]-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

RN 318987-49-4 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-  
methoxyethoxy)methyl]-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)


RN 318987-50-7 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-  
methoxyethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 318987-57-4 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1',8a-dicarboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-, 1'-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 318987-58-5 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1',8a-dicarboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-, 8a-ethyl 1'-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 318987-59-6 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 318987-71-2 CAPLUS


CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with (-)-ethyl 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 318987-70-1

CMF C28 H29 Cl N4 O6 S

Rotation (-).




CM 2

CRN 2743-38-6


CMF C18 H14 O8

CDES 1:R2:R\*,R\*


Absolute stereochemistry.




RN 318987-93-8 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 1'-(4-aminophenyl)-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-  
 (methoxymethyl)- (9CI) (CA INDEX NAME)



RN 318987-94-9 CAPLUS  
 CN Benzenecarboximide acid, 4-[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-5-oxospiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-1'-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 318988-00-0 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]-8a-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-03-3 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxaldehyde,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-




(9CI) (CA INDEX NAME)




RN 318988-05-5 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[[[(4-  
methylphenyl)sulfonyl]oxy]methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 318988-11-3 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-[2-  
(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 318988-12-4 CAPLUS


CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-  
[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 318988-14-6 CAPLUS  
 CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-[2-(methylthio)-4-  
 pyrimidinyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 318988-18-0 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-methyl-1'-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 318988-19-1 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-methyl- (9CI) (CA  
 INDEX NAME)




RN 318988-23-7 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-butanoic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(phenylmethyl)-,  
methyl ester (9CI) (CA INDEX NAME)




RN 318988-24-8 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-butanoic acid,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-, methyl ester (9CI)  
(CA INDEX NAME)




RN 318988-27-1 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-  
(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 318988-28-2 CAPLUS


CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)- (9CI)  
(CA INDEX NAME)




RN 318988-34-0 CAPLUS  
 CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318988-35-1 CAPLUS  
 CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 318988-36-2 CAPLUS  
 CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
 1-acetyl-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-  
 (methoxymethyl)-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 318988-37-3 CAPLUS  
 CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,  
 1-acetyl-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-

(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 318988-45-3 CAPLUS

CN Spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-7-carboxylic acid, 8a-[(acetyloxy)methyl]tetrahydro-5-oxo-1'-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 318988-46-4 CAPLUS

CN Spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-7-carboxylic acid, tetrahydro-8a-(hydroxymethyl)-5-oxo-1'-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 318988-47-5 CAPLUS


CN Spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-7-carboxylic acid, tetrahydro-8a-(hydroxymethyl)-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 318988-48-6 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 318988-49-7 CAPLUS  
 CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,  
 tetrahydro-8a-(hydroxymethyl)-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318988-53-3 CAPLUS  
 CN Spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-7-carboxylic acid,  
 tetrahydro-5-oxo-1'-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 318988-54-4 CAPLUS  
 CN Spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-7-carboxylic acid,  
 tetrahydro-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 318988-55-5 CAPLUS

CN Spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-7-carboxylic acid, tetrahydro-5-oxo-1'-(4-pyridinyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 318988-56-6 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 318988-57-7 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318988-58-8 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file uspatful; d que nos l20

FILE 'USPATFULL' ENTERED AT 11:35:57 ON 26 APR 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 25 Apr 2002 (20020425/PD)

FILE LAST UPDATED: 25 Apr 2002 (20020425/ED)

HIGHEST GRANTED PATENT NUMBER: US6378132

HIGHEST APPLICATION PUBLICATION NUMBER: US2002049999

CA INDEXING IS CURRENT THROUGH 25 Apr 2002 (20020425/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 25 Apr 2002 (20020425/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2002

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2002

```
>>> USPAT2 is now available.  USPATFULL contains full text of the  <<<
>>> original, i.e., the earliest published granted patents or  <<<
>>> applications.  USPAT2 contains full text of the latest US  <<<
>>> publications, starting in 2001, for the inventions covered in  <<<
>>> USPATFULL.  A USPATFULL record contains not only the original  <<<
>>> published document but also a list of any subsequent  <<<
>>> publications.  The publication number, patent kind code, and  <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.  <<<
```

```
>>> USPATFULL and USPAT2 can be accessed and searched together  <<<
>>> through the new cluster USPATAL.  Type FILE USPATAL to  <<<
>>> enter this cluster.  <<<
>>>  <<<
>>> Use USPATAL when searching terms such as patent assignees,  <<<
>>> classifications, or claims, that may potentially change from  <<<
>>> the earliest to the latest publication.  <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L9          STR
L10         STR
L11         STR
L12         STR
L13         STR
L14         STR
L15         STR
L16         STR
L18         147 SEA FILE=ZREGISTRY SSS FUL (L9 OR L10 OR L11 OR L12 OR L13 OR
           L14 OR L15 OR L16)
L20         0 SEA FILE=USPATFULL ABB=ON  PLU=ON  L18
```

=> file caold; d que nos l21

FILE 'CAOLD' ENTERED AT 11:36:14 ON 26 APR 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)



This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
L9          STR
L10         STR
L11         STR
L12         STR
L13         STR
L14         STR
L15         STR
L16         STR
L18         147 SEA FILE=ZREGISTRY SSS FUL (L9 OR L10 OR L11 OR L12 OR L13 OR
           L14 OR L15 OR L16)
L21         0 SEA FILE=CAOLD ABB=ON PLU=ON L18
```

=> file home

FILE 'HOME' ENTERED AT 11:36:19 ON 26 APR 2002